UPDATE: PTC Therapeutics (PTCT) Initiated Neutral at UBS
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $65.26 -0.17%
Rating Summary:
18 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Rating Summary:
18 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Join SI Premium – FREE
(Updated - October 27, 2020 5:00 PM EDT)
UBS analyst Colin Bristow started PTC Therapeutics (NASDAQ: PTCT) at Neutral, PT $55.00
You May Also Be Interested In
- PTC Therapeutics acquires Fabry disease gene therapy from Sangamo
- Nomura/Instinet Starts Chow Tai Seng Jewellery Co Ltd (002867:CH) at Neutral
- JPMorgan Resumes Oddity Tech Ltd (ODD) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
